Home/Pipeline/Taiho Oncology Pipeline

Taiho Oncology Pipeline

Various solid tumors

Multiple (I-III)ActiveN/A

Key Facts

Indication

Various solid tumors

Phase

Multiple (I-III)

Status

Active

Company

Otsuka Holdings

About Otsuka Holdings

Otsuka Holdings is a multinational healthcare leader founded on the mission 'Otsuka-people creating new products for better health worldwide.' It has achieved global prominence through flagship CNS drugs, a strategic stake in Lundbeck, and blockbuster nutraceutical brands like Pocari Sweat. The company's strategy is built on a diversified four-pillar business model—pharmaceuticals, nutraceuticals, medical devices, and chemicals—driven by a unique culture of creativity ('Souzoususei') and evidence-based validation ('Jisshou').

View full company profile

Therapeutic Areas

Central Nervous System Psychiatry Neurology Oncology Nephrology Cardiovascular

Other Various solid tumors Drugs

Drug	Company	Phase	Status
NUC-8232	NuCana	Phase 1	Active
TCR Library Program	Medigene	Discovery	Active
Guardant Infinity Biomarker Discovery	Guardant Health	Development/Commercial	Active
Cytotoxic Oncology Generic	MSN Laboratories	Pre‑clinical	Active
APCEDEN®	APAC Biotech	Approved	Commercial
Solid Tumor Profiling	Diatech Pharmacogenetics	Commercial	Active
BAVENCIO (avelumab)	EMD Serono	Approved	Active (Lifecycle Management)
FoundationOne®CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
FoundationOne®Liquid CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
177Lu‑BetaBart (RV‑01)	AtomVie Global Radiopharma	Phase 1/2a	Active
BeiGene Oncology Portfolio	EVA Pharma	Phase 2/3	Active
Bevacizumab Biosimilar	Bio Usawa Biotechnology	Preclinical	Active